SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Versant Venture Capital V, L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Crinetics Pharmaceuticals, Inc. [ CRNX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/04/2019
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2019		J(1)		445,470	D	$0	2,524,456	I	See Footnote(2)
Common Stock	02/04/2019		J(3)		13,387	D	$0	75,949	I	See Footnote(4)
Common Stock	02/04/2019		J(5)		14,828	D	$0	84,161	I	See Footnote(6)
Common Stock	02/04/2019		J(7)		33,903	D	$0	192,122	I	See Footnote(8)
Common Stock	02/04/2019		J(9)		9,473	A	$0	9,473	I	See Footnote(10)
Common Stock	02/04/2019		J(11)		9,473	D	$0	0	I	See Footnote(10)
Common Stock	02/04/2019		J(12)		678	A	$0	678	I	See Footnote(13)
Common Stock	02/04/2019		J(14)		678	D	$0	0	I	See Footnote(13)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person* Versant Venture Capital V, L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Affiliates Fund V, L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Ophthalmic Affiliates I, L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Venture Capital V (Canada), LP (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Ventures V, LLC (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* Versant Ventures V (Canada), L.P. (Last) (First) (Middle) ONE SANSOME STREET, SUITE 3630 (Street) SAN FRANCISCO CA 94104 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V, L.P. ("VVC V") without consideration to its partners.

2. These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein.

3. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Affiliates Fund V, L.P. ("VAF V") without consideration to its partners.

4. These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VAF V; however, they each disclaim beneficial ownership of the shares held by VAF V, except to the extent of their pecuniary interests therein.

5. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") without consideration to its partners.

6. These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VOA; however, they each disclaim beneficial ownership of the shares held by VOA, except to the extent of their pecuniary interests therein.

7. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V (Canada) LP ("VVC CAN") without consideration to its partners.

8. These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein.

9. Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA.

10. The shares are held VV V.

11. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members.

12. Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN.

13. The shares are held VV V CAN.

14. Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners.

	VERSANT VENTURE CAPITAL V, L.P. By: Versant Ventures V, LLC Its: General Partner By: /s/ Robin L. Praeger	02/06/2019
	VERSANT AFFILIATES FUND V, L.P. By: Versant Ventures V, LLC Its: General Partner By: /s/ Robin L. Praeger	02/06/2019
	VERSANT OPHTHALMIC AFFILIATES FUND I, L.P. By: Versant Ventures V, LLC Its: General Partner By: /s/ Robin L. Praeger	02/06/2019
	VERSANT VENTURE CAPITAL V (CANADA) LP By: Versant Ventures V (Canada), L.P. Its: General Partner By: Versant Ventures V GP-GP (Canada), Inc. Its: General Partner By: /s/ Robin L. Praeger	02/06/2019
	VERSANT VENTURES V, LLC By: /s/ Robin L. Praeger	02/06/2019
	VERSANT VENTURES V (CANADA), L.P. By: Versant Ventures V GP-GP (Canada), Inc. Its: General Partner By: /s/ Robin L. Praeger	02/06/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.